Table 2.
Transplant characteristics
| Variable | SD |
URD |
||||
|---|---|---|---|---|---|---|
| No. assessable | No. | % | No. assessable | No. | % | |
| Graft source | 3191 | 2370 | ||||
| Bone marrow | 806 | 25 | 1081 | 46 | ||
| Peripheral blood | 2385 | 75 | 1289 | 54 | ||
| Preparative regimen | 3191 | 2370 | ||||
| Myeloablative | 2463 | 78 | 1882 | 79 | ||
| Reduced intensity | 689 | 22 | 488 | 21 | ||
| Other | 39 | 1 | ||||
| GVHD prophylaxis | 3191 | 2370 | ||||
| CSA + MTX ± other | 2683 | 84 | 1208 | 51 | ||
| Tacrolimus + MTX ± other | 484 | 15 | 1140 | 48 | ||
| Other | 24 | 1 | 22 | 1 | ||
| HLA high-resolution typing, -A, -B, -C, and -DRB1 (URD only) | 2370 | |||||
| 8/8 matched | 1532 | 65 | ||||
| 7/8 | 614 | 26 | ||||
| ≤ 6/8 | 224 | 9 | ||||
| Year of transplant | 3191 | 2370 | ||||
| 1999 | 498 | 16 | 233 | 10 | ||
| 2000 | 478 | 15 | 284 | 12 | ||
| 2001 | 453 | 14 | 266 | 11 | ||
| 2002 | 446 | 14 | 239 | 10 | ||
| 2003 | 350 | 11 | 340 | 14 | ||
| 2004 | 503 | 16 | 486 | 21 | ||
| 2005 | 463 | 15 | 522 | 22 | ||
| AGVHD grades B-D | 3191 | 2370 | ||||
| No | 1952 | 61 | 969 | 41 | ||
| Yes | 1239 | 39 | 1401 | 59 | ||
| AGVHD grades C-D | 3191 | 2370 | ||||
| No | 2692 | 84 | 1618 | 68 | ||
| Yes | 499 | 18 | 752 | 32 | ||
| AGVHD organ | ||||||
| Skin | 3191 | 2370 | ||||
| Stage 0 | 325 | 20 | 264 | 16 | ||
| Stage 1 | 522 | 32 | 313 | 19 | ||
| Stage 2 | 482 | 29 | 479 | 29 | ||
| Stage 3 | 274 | 17 | 502 | 30 | ||
| Stage 4 | 46 | 3 | 9 | 5 | ||
| GI | 3191 | 2370 | ||||
| Stage 0 | 922 | 56 | 820 | 50 | ||
| Stage 1 | 309 | 19 | 392 | 24 | ||
| Stage 2 | 152 | 9 | 123 | 7 | ||
| Stage 3 | 138 | 8 | 134 | 8 | ||
| Stage 4 | 118 | 7 | 176 | 11 | ||
| Liver | 3191 | 2370 | ||||
| Stage 0 | 1121 | 69 | 1160 | 71 | ||
| Stage 1 | 154 | 9 | 112 | 7 | ||
| Stage 2 | 114 | 7 | 127 | 8 | ||
| Stage 3 | 127 | 8 | 112 | 7 | ||
| Stage 4 | 108 | 7 | 117 | 7 | ||
| AGVHD organ involvement combination | ||||||
| Skin + GI + liver | 234 | 15 | 282 | 18 | ||
| Skin + GI | 262 | 17 | 342 | 21 | ||
| Skin + liver | 158 | 10 | 119 | 7 | ||
| GI + liver | 69 | 4 | 50 | 3 | ||
| Skin | 670 | 42 | 641 | 40 | ||
| GI | 152 | 10 | 151 | 9 | ||
| Liver | 42 | 3 | 17 | 1 | ||
Other GVHD prophylaxis include for SD, MTX ± other (no MMF) 16, MMF ± other (no MTX) 1, steroids ± other (no MTX or MMF) 1, MTX + MMF ± other 3, unknown 3; and for URD, MTX ± other (no MMF) 8, MMF ± other (no MTX) 3, MTX + MMF ± other 4, unknown 7.
CSA indicates cyclosporine; MTX, methotrexate; GI, gastrointestinal; and MMF, mycophenolate mofetil.